Status:
COMPLETED
Study Evaluating Vaccine in Adults With HIV
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to learn whether the study vaccine and adjuvants (drugs that are used to help improve immune responses) have an acceptable safety profile in treating individuals with HIV....
Eligibility Criteria
Inclusion
- 18 years of age diagnosed with HIV and on stable HAART for a minimum of six months
- CD4 T-cell count greater than and equal to 350/mm3 at screening
- No reported CD4 T-cell count less than 350/mm3 at any time before screening
- Viral load less than 50 copies/mL at screening and no viral load greater than 400 copies/mL for a minimum of six months prior to screening
Exclusion
- Any chronic symptomatic infection other than HIV
- Use of any prior HIV vaccine (prophylactic and/or therapeutic) within one year before or during screening
- Any malignancy that may require systemic therapy
- Use of any investigational treatment within six months before screening or planned during study enrollment, except for investigational retrovirals obtained through ACTG
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
End Date :
February 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00195234
Start Date
December 1 2004
End Date
February 1 2007
Last Update
December 5 2007
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Sacramento, California, United States, 95817
2
Denver, Colorado, United States, 80262
3
Chicago, Illinois, United States, 60612
4
New York, New York, United States, 10003